🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. logo
Market Cap: Highest
Employees: Medium

CAPLYTA

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.

Tags: biopharmaceutical, bipolar depression, central nervous system, drug development, neurologic diseases, neuropsychiatric, schizophrenia

Symbol: ITCI

Recent Price: $83.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. Sharon Mates Ph.D.

Sector: Healthcare

Employees: 610

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 440 9333

Leadership

  • Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
  • Michael I. Halstead, J.D., President
  • Mark Neumann, Executive Vice President, Chief Commercial Officer
  • Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
  • Sanjeev Narula, Executive Vice President, Chief Financial Officer
  • John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
  • Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
  • Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
  • Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
  • Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
  • Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
  • Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
  • Rory B. Riggs, MBA, Co-Founder and Director
  • E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
  • Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals

Last updated: 2024-12-31